Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-04-14
2011-10-04
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S192100, C514S001100, C514S013300, C514S021200, C530S350000
Reexamination Certificate
active
08029791
ABSTRACT:
Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
REFERENCES:
patent: 5712380 (1998-01-01), Kendall et al.
patent: 6011003 (2000-01-01), Charnock-Jones et al.
patent: 6100071 (2000-08-01), Davis-Smyth et al.
patent: 6897294 (2005-05-01), Davis-Smyth et al.
patent: 7279159 (2007-10-01), Daly et al.
patent: 7396664 (2008-07-01), Daly et al.
patent: 2005/0043236 (2005-02-01), Daly et al.
patent: 2005/0281831 (2005-12-01), Davis-Smyth et al.
patent: 2006/0058234 (2006-03-01), Daly et al.
patent: WO97/44453 (1997-11-01), None
patent: WO98/13071 (1998-04-01), None
patent: WO99/03996 (1999-01-01), None
Terman et al., 1991, “Identification of a new endothelial cell growth factor receptor tyrosine kinase”, Oncogene 6:1677-1683.
Terman et al., 1992, “Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor”, Biochem Biophys Res Comm 187(3):1579-1586.
Tsutsumi et al., 1997, “PEGylation of interleukin-6 effectively increases its thrombopoietic potency”, Thrombosis and Haemostasis 77(1):168-173.
Dunca and Spreafico 1994, “Polymer Conjugates”, Drug Delivery Systems 27(4):290-306.
Hileman et al., 1998, “Glycosaminoglycan-protein interactions: definitions of consensus sites in glycosaminoglycan binding proteins”, BioEssays 20:156-167.
Devries et al., 1992, “The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor”, Science 225:989-991.
Sharifi et al., 1998, “Improving monoclonal antibody pharmacokinetics via chemical modification”, Quart J Nucl Med 42:242-249.
Jensen-Pippo et al.,1996, “Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol)”, Pharm Res 13(1)102-107.
Tanaka et al., 1997, “Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 Tyrosine kinase)”, Jpn J Cancer Res 88:867-876.
Yang et al., 1995, “The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma”, Cancer 76(4): 687-694.
Davis-Smyth et al., 1996, “The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade”, The EMBO Journal 15(18):4919-4927.
Davis Samuel
Papadopoulos Nicholas J.
Yancopoulos George D.
Cottingham Frank R.
Gregg Valeta
Lockard Jon M
Regeneron Pharmaceuticals Inc.
Saoud Christine J
LandOfFree
Modified chimeric polypeptides with improved pharmacokinetic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified chimeric polypeptides with improved pharmacokinetic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified chimeric polypeptides with improved pharmacokinetic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4287864